Invex Therapeutics Cash Flow Statement

Financials in millions AUD. Fiscal year is July - June.

Millions AUD. Fiscal year is Jul - Jun.

Fiscal Year	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021	2019 - 2020
Period Ending	Jun '25 Jun 30, 2025	Jun '24 Jun 30, 2024	Jun '23 Jun 30, 2023	Jun '22 Jun 30, 2022	Jun '21 Jun 30, 2021	2019 - 2020
Net Income	-0.48	-1.64	-7.75	-3.95	-2.28	Upgrade
Stock-Based Compensation	0.02	0.14	0.48	0.35	0.56	Upgrade
Other Operating Activities	0.02	-0.04	0.02	0	0	Upgrade
Change in Accounts Receivable	-0	0.24	-0.19	-0.12	0.1	Upgrade
Change in Accounts Payable	-0.21	-1.14	0.57	0.35	-0.05	Upgrade
Operating Cash Flow	-0.65	-2.44	-6.87	-3.38	-1.68	Upgrade
Issuance of Common Stock	-	-	-	-	8.65	Upgrade
Repurchase of Common Stock	-	-14	-	-	-	Upgrade
Other Financing Activities	-	-	-	-	-0.55	Upgrade
Financing Cash Flow	-	-14	-	-	8.09	Upgrade
Foreign Exchange Rate Adjustments	0	-	-	-	-	Upgrade
Net Cash Flow	-0.65	-16.45	-6.87	-3.38	6.42	Upgrade
Cash Income Tax Paid	-0.23	-1.21	-0.46	-	-	Upgrade
Levered Free Cash Flow	-0.64	-2.1	-4.48	-1.95	-2.23	Upgrade
Unlevered Free Cash Flow	-0.64	-2.1	-4.48	-1.95	-2.23	Upgrade
Change in Working Capital	-0.21	-0.9	0.38	0.22	0.04	Upgrade

Updated Jun 30, 2025. Source: S&P Global Market Intelligence. Standard template. Financial Sources.